The Medicines Company has sold its infectious disease business, which it had built up in recent years with the acquisitions of Targanta Therapeutics and Rempex, to Melinta Therapeutics for US$270 M. The company has been undergoing a strategic restructuring exercise involving the divestiture of non-core areas leaving itself with a single marketed product. It is also focusing its efforts on developing inclisiran, which is in Phase III development for the treatment of hypercholesterolemia.